Literature DB >> 34594120

Use of Anthropometric Measures of Obesity to Predict Diabetic Retinopathy in Patients with Type 2 Diabetes in China.

Qiu-Xue Yi1, Li-Na Zhu1, Jing Ma2, Xin-Jie Yu1, Lin Liu1, Jie Shen1.   

Abstract

PURPOSE: Obesity is an established risk factor for type 2 diabetes (T2D). Diabetic retinopathy (DR) is a major microvascular complication of T2D. In this cross-sectional study, we investigated the association between various anthropometric indices of obesity and DR. PATIENTS AND METHODS: A representative sample of 1952 patients with T2D participated in this cross-sectional study conducted in Shanghai, China. Anthropometric measures of obesity including weight, height, waist circumference, hip circumference, body mass index (BMI), waist-to-hip ratio (WHR), and waist-to-height ratio (WHtR) were evaluated. The association between WHtR, WHR, and BMI and the presence of DR was examined with logistic regression models.
RESULTS: The prevalence of DR was higher in T2D patients with high WHtR compared to those with normal WHtR (p<0.05). A higher BMI was associated with elevated risk of DR (model 1, p=0.034; model 2, p=0.036). WHR was unrelated to the occurrence of DR (p>0.05).
CONCLUSION: WHtR and BMI but not WHR are risk factors for DR in obese patients with T2D. Patients with high WHtR and BMI should be closely monitored to prevent the development of DR.
© 2021 Yi et al.

Entities:  

Keywords:  BMI; T2D; WHR; WHtR; diabetic retinopathy; obesity; risk factor

Year:  2021        PMID: 34594120      PMCID: PMC8477615          DOI: 10.2147/DMSO.S321030

Source DB:  PubMed          Journal:  Diabetes Metab Syndr Obes        ISSN: 1178-7007            Impact factor:   3.168


Introduction

The global prevalence of diabetes is increasing1,2 with 382 million patients worldwide and 98 million in China reported in 2013,3 constituting a major public health issue and burden. Diabetic retinopathy (DR), a chronic microvascular complication of diabetes mellitus, is the leading cause of blindness in working adults.4,5 A meta-analysis of epidemiologic studies in China showed that the prevalence of DR and nonproliferative and proliferative DR in diabetes patients was 23.0%, 19.1%, and 2.8%.2 Strategies to reduce the burden of DR are therefore needed; this requires identification of the risk factors of DR, which have not been extensively studied in patients with diabetes.6 The World Health Organization (WHO) classifies obesity in 2 different ways:2 generalized obesity is determined by body mass index (BMI, calculated as weight in kg divided by height in m2), while central/abdominal obesity is assessed by waist circumference (WC) or waist-to-hip ratio (WHR). Obesity is an known risk factor for type 2 diabetes (T2D) and may contribute to the pathogenesis of DR.7 Body weight, BMI, WC, and WHR were positively associated with incidence of diabetes in a Canadian study,8 and waist-to-height ratio (WHtR) was shown to be a better predictor of diabetes than other anthropometric measures in the Jordanian population.9 Among anthropometric indices, BMI showed comparable performance to WC, WHtR, and WHR in predicting T2DM in American males.10 However, clear evidence of an association between generalized and abdominal obesity and DR risk is lacking. In this study, we investigated the associations between different anthropometric measures of obesity and the occurrence and severity of DR in a well-characterized sample of Chinese patients with T2D.

Materials and Methods

Study Population

This cross-sectional study conducted at Renji Hospital Affiliated With Shanghai Jiao tong University School of Medicine included patients from the local population (Pujiang Town, Minhang District, Shanghai) who were diagnosed with T2D between December 2016 and March 2017. A questionnaire and physical examinations were completed by physicians and nurses, and blood testing was performed in the laboratory of Renji Hospital. All patients provided written, informed consent for their participation in the study, and the protocol was approved by the Ethics Committee of Renji Hospital. The study sample included 1952 individuals with physician-diagnosed T2D aged 64.30±7.56 years from the Pujiang Town database. Patients with severe hepatic and renal dysfunction, severe psychiatric disturbance, or malignant tumors or who had difficulty completing the examinations were excluded.

Questionnaire

All participants underwent a standardized interview to complete a questionnaire that covered duration of diabetes, socioeconomic measures (eg, income, education), lifestyle risk factors (eg, smoking), medication use, and self-reported history of systemic diseases including myocardial infarction and stroke. Participants were assisted in completing the questionnaire by trained nurses if necessary.

Measurements

For all measurements, participants were required to remove their shoes and heavy objects. Height was measured in cm and weight in kg. BMI, calculated as weight in kg divided by height in m2, was used to categorize patients as under/normal weight (BMI <23), overweight (BMI 23–27.5), or obese (BMI >27.5) according to cutoff points for obesity in Asians recommended by the WHO.17 WC (in cm) was taken at the smallest horizontal distance between the costal margins and iliac crests at the end of tidal expiration, while hip circumference (in cm) was measured at the maximal protuberance of the buttocks. WHR was calculated by dividing WC by hip circumference, and WHtR was calculated by dividing WC by height. Blood pressure (BP) taken from the right arm after 10 min of rest. Hypertension was defined as systolic BP ≥140 mmHg, diastolic BP of 90 mmHg, or use of antihypertensive medication. Venous blood samples were drawn and sent for analysis of fasting plasma glucose (FPG), 2-h postprandial plasma glucose (PPG), glycated hemoglobin (HbA1c), C-peptide, insulin, serum total bilirubin, aspartate aminotransferase, alanine aminotransferase, high density lipoprotein (HDL), low density lipoprotein (LDL), total cholesterol (TC), and triglycerides (TG) at the Renji Hospital laboratory. Hyperlipidemia was defined as TC ≥6.2 mmol/l or use of lipid-lowering drugs.

Ophthalmologic Examinations

All patients underwent an ophthalmologic examination that included best corrected visual acuity and funduscopic examinations by ophthalmic technician; the fundus photographs were analyzed by retina specialists. DR was evaluated by 2-field digital color fundus photography of each eye using a digital retinal camera (Canon, Tokyo, Japan). The photographed fields were the macula, optic disc, and area nasal to the optic disc. Retinopathy was graded based on the worst eye and the severity score was determined according to a modified version of the Early Treatment Diabetic Retinopathy Study grading system.

Statistical Analysis

Statistical analyses were performed using SAS v6.5 software (SAS Institute, Cary, NC, USA). Normally distributed continuous data are expressed as mean±standard deviation and categorical data are presented as proportions. The characteristics of patients with and without DR were compared with the independent samples t-test for normally distributed continuous variables and with the χ2 test for categorical variables. To assess risk factors for DR and age-adjusted prevalence, we used logistic regression models with DR as the dependent variable, and report the results as odds ratio (OR) with 95% confidence interval (CI) and percentage. Two-tailed p values <0.05 were considered statistically significant.

Results

Demographic Characteristics of the Study Population

Of the 1952 patients with T2D, 161 with ungradable fundus photographs were excluded; 1791 were ultimately enrolled in the study. There were 1301 T2DM patients with no DR; thus, the prevalence of DR was 27.36% (range: 18–45%), with no statistically significant difference across age groups (Table 1). The DR group was younger than the non-DR group (p=0.0001), but the proportion of males was similar between groups (Table 2).
Table 1

Prevalence of Diabetic Retinopathy in Patients with Type 2 Diabetes

Age Range, Years
40–5050–6060–7070–80≥80
Male45.45%29.25%27.46%20.89%25.00%
Female26.67%30.90%29.98%19.65%18.18%
Total37.84%30.20%28.81%20.16%20.59%
Table 2

Characteristics of Patients with Type 2 Diabetes

VariableTotal (n=1791)Non-DR (n=1301)DR (n=490)p
Age, years64.30±7.5664.7±7.6763.2±7.160.0001
Male790 (44.11%)576 (44.27%)214 (43.67%)0.8196
Duration of diabetes, years8.92±5.958.25±5.610.68±6.4<0.0001
Insulin therapy239 (86.65%)119 (9.15%)120 (24.49%)<0.0001
Systolic BP, mmHg147.92±20.4146.7±19.8151.4±21.3<0.0001
Waist circumference90.22±9.2090.49±9.1289.51±9.400.0492
Hip circumference98.13±7.2498.36±7.091497.53±7.600.0325
BMI, kg/m26.56±3.3826.64±3.3726.35±3.400.1031
WHR0.92±0.060.92±0.060.92±0.070.547
WHtR0.57±0.060.57±0.060.56±0.0030.051

Note: Data are presented as mean±standard deviation or n (%).

Abbreviations: BMI, body mass index; BP, blood pressure; DR, diabetic retinopathy; WHR, waist-to-hip ratio; WHtR, weight-to-height ratio.

Prevalence of Diabetic Retinopathy in Patients with Type 2 Diabetes Characteristics of Patients with Type 2 Diabetes Note: Data are presented as mean±standard deviation or n (%). Abbreviations: BMI, body mass index; BP, blood pressure; DR, diabetic retinopathy; WHR, waist-to-hip ratio; WHtR, weight-to-height ratio.

Clinical Characteristics of the Study Population

Compared to the non-DR group, T2DM patients in the DR group had a longer disease duration and higher systolic BP, and a higher proportion had received insulin therapy (all p<0.001). Anthropometric indices did not differ significantly between non-DR and DR groups (Table 2). T2DM patients with DR had higher FPG, PPG, and HbA1c than those without DR (all p<0.001) (Table 3). The age-adjusted analysis showed similar results (Table 4). There were no significant differences in serum TC, TG, HDL, and LDL between groups.
Table 3

Biochemical Characteristics of Patients with Type 2 Diabetes

ParameterTotal (n=1791)Non-DR (n=1301)DR (n=490)p
FPG, mmol/l8.76±2.588.43±2.389.63±2.88<0.0001
PPG, mmol/l15.32±4.3914.84±4.2216.60±4.57<0.0001
HbA1c, %7.16±1.526.95±1.447.83±1.60<0.0001
FINS7.95±5.448.25±5.887.08±3.91<0.0001
PINS30.23±22.4232.27±23.6124.19±17.77<0.0001
FCP1.19±1.011.28±1.241.09±0.780.154
PCP2.60±1.802.99±2.042.29±1.510.003
Total cholesterol5.25±1.165.24±1.125.25±1.240.8745
Triglycerides1.83±1.531.86±1.451.78±1.700.3939
HDL1.52±0.371.51±0.351.53±0.410.2867
LDL2.80±0.762.80±0.732.81±0.810.7362

Note: Data are presented as mean±standard deviation.

Abbreviations: DR, diabetic retinopathy; FCP, fasting C-peptide; FINS, fasting insulin; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; HDL, high density lipoprotein; LDL, low density lipoprotein; PCP, postprandial C-peptide; PINS, postprandial insulin; PPG, postprandial plasma glucose.

Table 4

Univariate Logistic Regression Analysis of Diabetic Retinopathy

Risk FactorOdds Ratio95% CIp
Age, per 10 years0.80.701–0.9120.0009
DM duration, per 5 years1.4311.303–1.571<0.0001
Insulin therapy3.2352.443–4.283<0.0001
FPG, mmol/l1.3481.261–1.441<0.0001
PPG, mmol/l1.1231.089–1.159<0.0001
HbA1c, %1.3581.266–1.456<0.0001
Systolic BP, per 10 mmHg1.151.078–1.226<0.0001
PINS/FINS0.820.764–0.88<0.0001
PCP/FCP0.9150.768–1.0890.3173

Abbreviations: BP, blood pressure; CI, confidence interval; DM, diabetes mellitus; FCP, fasting C-peptide; FINS, fasting insulin; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; PCP, postprandial C-peptide; PINS, postprandial insulin; PPG, postprandial plasma glucose.

Biochemical Characteristics of Patients with Type 2 Diabetes Note: Data are presented as mean±standard deviation. Abbreviations: DR, diabetic retinopathy; FCP, fasting C-peptide; FINS, fasting insulin; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; HDL, high density lipoprotein; LDL, low density lipoprotein; PCP, postprandial C-peptide; PINS, postprandial insulin; PPG, postprandial plasma glucose. Univariate Logistic Regression Analysis of Diabetic Retinopathy Abbreviations: BP, blood pressure; CI, confidence interval; DM, diabetes mellitus; FCP, fasting C-peptide; FINS, fasting insulin; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; PCP, postprandial C-peptide; PINS, postprandial insulin; PPG, postprandial plasma glucose.

Association Between Diabetes Indices and DR Risk

Younger age; longer duration of DM and insulin therapy; and higher FPG, PPG, HbA1c, postprandial insulin to fasting insulin ratio, postprandial C-peptide to fasting C-peptide ratio, and systolic BP were associated with higher risk of DR in T2D patients (Table 5). Among anthropometric measures of obesity, higher BMI was associated with higher risk of DR (model 1, p=0.034; model 2, p=0.036) (Table 6), while WHR was unrelated to DR (p>0.05) (Table 7). We also found that high WHtR was more closely associated with DR than a normal WHtR (p<0.05) (Table 8).
Table 5

Age-Adjusted Univariate Logistic Regression Analysis of Diabetic Retinopathy

Risk FactorOdds Ratio95% CIp
DM duration, per 5 years1.4881.352–1.538<0.0001
Insulin therapy3.2042.417–4.248<0.0001
FPG, mmol/l1.3341.1248–1.427<0.0001
PPG, mmol/l1.1221.087–1.158<0.0001
HbA1c, %1.3451.254–1.442<0.0001
Systolic BP, per 10 mmHg1.1821.107–1.262<0.0001
PINS/FINS0.8220.766–0.883<0.0001
PCP/FCP0.9450.918–0.9860.5332

Abbreviations: BP, blood pressure; CI, confidence interval; DM, diabetes mellitus; FCP, fasting C-peptide; FINS, fasting insulin; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; PCP, postprandial C-peptide; PINS, postprandial insulin; PPG, postprandial plasma glucose.

Table 6

Association Between BMI and the Presence of Diabetic Retinopathy

BMIOR95% CIpAge-Adjusted
OR95% CIp
<231 [Reference]1 [Reference]
23–27.51.4121.027–1.9420.0341.4091.023–1.9410.036
>27.51.1160.877–1.4190.3731.1160.877–1.4190.373

Abbreviations: BMI, body mass index; CI, confidence interval; OR, odds ratio.

Table 7

Association Between WHR and the Presence of Diabetic Retinopathy

WHROR95% CIpAge-Adjusted
OR95% CIp
≤0.91 [Reference]1 [Reference]
>0.90.9940.802–1.2310.9541.0040.809–1.2450.974

Abbreviations: CI, confidence interval; OR, odds ratio; WHR, waist-to-hip ratio.

Table 8

Association Between WHtR and the Presence of Diabetic Retinopathy

WHtROR95% CIpAge-Adjusted
OR95% CIp
≤0.551 [Reference]1 [Reference]
>0.551.2571.1019–1.5520.00331.2771.029–1.5840.026

Abbreviations: CI, confidence interval; OR, odds ratio; WHtR, weight-to-height ratio.

Age-Adjusted Univariate Logistic Regression Analysis of Diabetic Retinopathy Abbreviations: BP, blood pressure; CI, confidence interval; DM, diabetes mellitus; FCP, fasting C-peptide; FINS, fasting insulin; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; PCP, postprandial C-peptide; PINS, postprandial insulin; PPG, postprandial plasma glucose. Association Between BMI and the Presence of Diabetic Retinopathy Abbreviations: BMI, body mass index; CI, confidence interval; OR, odds ratio. Association Between WHR and the Presence of Diabetic Retinopathy Abbreviations: CI, confidence interval; OR, odds ratio; WHR, waist-to-hip ratio. Association Between WHtR and the Presence of Diabetic Retinopathy Abbreviations: CI, confidence interval; OR, odds ratio; WHtR, weight-to-height ratio.

Discussion

The overall age-/sex-standardized prevalence of DR was 27.36% in our study; this is within the range of 11.9–43.1% that has been reported in China. Previously identified risk factors for DR including longer diabetes duration and higher plasma glucose, HbA1c, insulin level, and systolic BP2,5,6,11—were also confirmed by our data. Patients with T2D in previous studies were mostly elderly and had comorbidities, which increased their frailty.12 As we did not collect complete medical history data for our cohort we could not confirm frailty profiles, which will be a part of a future investigation. We also collected physical and laboratory data on a single occasion for each patient, which may not have been sufficient to identify all potential comorbidities. In the REPOSI study, sex influenced the occurrence of DR in T2D patients;13 however, we found that sex was unrelated to the prevalence of DR. The discrepancy between our findings and the earlier report may be attributable to sex differences in frailty or other factors such as ethnicity, geography, and lifestyle. Additionally, our results are not generalizable to a younger population of T2D patients because of the age range of our cohort. Controlling glycemic index is important for preventing acute coronary syndrome in T2D.14,15 In the multicenter, randomized controlled Diabetes Control and Complications Trial investigating the relationship between glycemic control and retinal, renal, and neurologic complications of type 1 diabetes mellitus, patients who received intensive treatment had a decreased risk of DR progression; however, the frequency of severe hypoglycemic events and excess weight gain was increased 3 fold.16–19 Strict blood glucose control increases the risk of hypoglycemia. On the other hand, in the United Kingdom Prospective Diabetes Study, intensive blood glucose control decreased the risk of microvascular complications in newly diagnosed T2D patients; it also decreased the risk of retinal photocoagulation by 29%, DR progression by 17%, vitreous hemorrhage by 23%, and legal blindness by 16% compared to patients receiving conventional treatment.20,21 Similarly, we found that for each 1% decrease in HbA1c (eg, from 9% to 8.1%), there was a 34% decrease in the risk of DR over a range of HbA1c values. Based on this result, we conclude that patients with T2D with DR should maintain strict glycemic control while avoiding hypoglycemia. With the increased development and deployment of digital technologies along with the circumstances surrounding the COVID-19 pandemic, telemedicine has become the safest mode of interaction between ophthalmologists and patients.22,23 In Shanghai, telemedicine is being implemented for DR screening and for the daily clinical work at our hospital and community health center. However, we did not use telemedicine in 2016 when the present study was initiated. We investigated the association between generalized obesity (as reflected by BMI) and abdominal obesity (as reflected by WHR and WHtR) and the presence of DR in T2D patients from Pujiang Town (Shanghai) and found a positive correlation between BMI and WHtR but not WHR and the presence of DR. These results suggest that abdominal and generalized obesity play an important role in the pathophysiology of DR in patients with T2D. It is interesting to note that while both WHR and WHtR are measures of abdominal obesity, their association with DR differed. Higher WHtR was related to enhanced risk of DR, which was not reported in previous studies that used WHR or WC as markers of abdominal obesity. WC is the most direct and simple index of abdominal obesity, which is also known as visceral obesity and refers to excess intra-abdominal adipose tissue accumulation.24 It has been demonstrated that the OR of DR was 1.28 per 5-cm increase in WC (CI: 1.05–1.56; P=0.014) and that WC has low sensitivity for predicting DR.25,26 WHtR is a measure of WC relative to height and is considered as a more useful metric to screen for cardiometabolic diseases.27 A study investigating WHR and WHtR cutoffs in obesity showed that the latter had higher sensitivity and specificity in both sexes and across all age groups.28 Thus, WHtR is a good measure of abdominal obesity, and our results showed that it can be used to predict the occurrence of DR in obese patients with T2D. In a cohort of T2D patients, WHR was positively associated with the risk of developing retinopathy.29 However, in another study, WHR was not a stable risk marker for predicting the occurrence of DR in T2D patients.30 Thus, additional research is needed to clarify the potential association between WHR and DR in different populations. Generalized obesity is linked to DR; our observation that BMI was positively associated with the occurrence of DR was not consistent with previous work demonstrating a nonsignificant or inverse association between BMI and DR.29,31,32 However, these studies did not account for the mutually confounding effects of generalized and abdominal obesity, which may have influenced the conclusions. Although the detailed pathophysiologic basis for the association between WHtR and DR is unclear, abdominal obesity is known to contribute to insulin resistance and inflammation, which are implicated in DR pathogenesis.33–35 The link between abdominal obesity and T2D is well established,24 and WHtR is considered as a better measure of abdominal obesity than WC and WHR. In addition to simple anthropometric measurements, 3-dimensional body-scanning techniques can be used to measure abdominal volume and shape,36 which can reveal functional aspects of abdominal fat such as brown adipose tissue and fatty acid composition that may be applicable to studies on the relationship between abdominal obesity and DR, and can guide interventions for DR prevention and treatment. This study had some limitations. Firstly, because of the cross-sectional design, causality and the temporal sequence of the observed associations could not be established. Secondly, as a hospital-based study, the recruited patients were not necessarily representative of the overall population with T2D. Finally, the 2-field fundus photographs used to evaluate DR may have yielded an underestimation of DR occurrence.

Conclusion

In summary, this study showed that BMI and WHtR were positively associated with the presence and severity of DR in T2D patients, while WHR was unrelated to DR. Longitudinal studies are needed to confirm the role of abdominal obesity in the pathogenesis of DR and to validate WHtR as a risk marker for DR in obese patients with T2D.
  35 in total

1.  Defining Aging Phenotypes and Related Outcomes: Clues to Recognize Frailty in Hospitalized Older Patients.

Authors:  Maura Marcucci; Carlotta Franchi; Alessandro Nobili; Pier Mannuccio Mannucci; Ilaria Ardoino
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2017-03-01       Impact factor: 6.053

2.  Prevalence and control of diabetes in Chinese adults.

Authors:  Yu Xu; Limin Wang; Jiang He; Yufang Bi; Mian Li; Tiange Wang; Linhong Wang; Yong Jiang; Meng Dai; Jieli Lu; Min Xu; Yichong Li; Nan Hu; Jianhong Li; Shengquan Mi; Chung-Shiuan Chen; Guangwei Li; Yiming Mu; Jiajun Zhao; Lingzhi Kong; Jialun Chen; Shenghan Lai; Weiqing Wang; Wenhua Zhao; Guang Ning
Journal:  JAMA       Date:  2013-09-04       Impact factor: 56.272

3.  C-reactive protein, body mass index, and diabetic retinopathy.

Authors:  Laurence Shen Lim; E Shyong Tai; Paul Mitchell; Jie Jin Wang; Wan Ting Tay; Ecosse Lamoureux; Tien Yin Wong
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-09       Impact factor: 4.799

4.  Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus.

Authors: 
Journal:  JAMA       Date:  2002-05-15       Impact factor: 56.272

5.  Gender-differences in disease distribution and outcome in hospitalized elderly: data from the REPOSI study.

Authors:  S Corrao; P Santalucia; C Argano; C D Djade; E Barone; M Tettamanti; L Pasina; C Franchi; T Kamal Eldin; A Marengoni; F Salerno; M Marcucci; P M Mannucci; A Nobili
Journal:  Eur J Intern Med       Date:  2014-07-19       Impact factor: 4.487

6.  Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group.

Authors: 
Journal:  Ophthalmology       Date:  1995-04       Impact factor: 12.079

7.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

Review 8.  Global prevalence and major risk factors of diabetic retinopathy.

Authors:  Joanne W Y Yau; Sophie L Rogers; Ryo Kawasaki; Ecosse L Lamoureux; Jonathan W Kowalski; Toke Bek; Shih-Jen Chen; Jacqueline M Dekker; Astrid Fletcher; Jakob Grauslund; Steven Haffner; Richard F Hamman; M Kamran Ikram; Takamasa Kayama; Barbara E K Klein; Ronald Klein; Sannapaneni Krishnaiah; Korapat Mayurasakorn; Joseph P O'Hare; Trevor J Orchard; Massimo Porta; Mohan Rema; Monique S Roy; Tarun Sharma; Jonathan Shaw; Hugh Taylor; James M Tielsch; Rohit Varma; Jie Jin Wang; Ningli Wang; Sheila West; Liang Xu; Miho Yasuda; Xinzhi Zhang; Paul Mitchell; Tien Y Wong
Journal:  Diabetes Care       Date:  2012-02-01       Impact factor: 19.112

9.  The performance of anthropometric measures to predict diabetes mellitus and hypertension among adults in Jordan.

Authors:  Yousef Khader; Anwar Batieha; Hashem Jaddou; Mohammed El-Khateeb; Kamel Ajlouni
Journal:  BMC Public Health       Date:  2019-10-29       Impact factor: 3.295

Review 10.  The Importance of Telemedicine during COVID-19 Pandemic: A Focus on Diabetic Retinopathy.

Authors:  Raffaele Galiero; Pia Clara Pafundi; Riccardo Nevola; Luca Rinaldi; Carlo Acierno; Alfredo Caturano; Teresa Salvatore; Luigi Elio Adinolfi; Ciro Costagliola; Ferdinando Carlo Sasso
Journal:  J Diabetes Res       Date:  2020-10-14       Impact factor: 4.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.